Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide"...Konipineni S, Valecha J, Meme CD, et al. Am J Cardiovasc Drugs 26, 507–509 (2026).
This letter addresses the use of trial sequential analysis (TSA) in evaluating colchicine for secondary prevention of cardiovascular disease (CVD), responding to comments by Konipineni et al. The authors acknowledge TSA’s benefits but highlight its limitations, including sensitivity to assumptions a...
| Publicado en: | American Journal of Cardiovascular Drugs Vol. 26; no. 4; pp. 511 - 513 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | letter response Journal Article |
| Publicado: |
Springer Nature
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194518059&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194518059 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11753277 G7S jtl: American Journal of Cardiovascular Drugs issn: 11753277 maglogo: N pubinfo: dt: Jul2026 vid: 26 iid: 4 pid: 87227 pub: Springer Nature artinfo: ui: 194518059 193833949 194518059 194518059 10.1007/s40256-026-00800-0 194518059 ppf: 511 ppct: 2 formats: tig: atl: Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide"...Konipineni S, Valecha J, Meme CD, et al. Am J Cardiovasc Drugs 26, 507–509 (2026). aug: au: Li, Hoi-Ying Cheriyan, Joseph Chan, Tsz-Kwan Yiu, Kai-Hang Tse, Hung-Fat Wilkinson, Ian B. Chan, Yap-Hang affil: https://ror.org/02zhqgq86 Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China sug: subj: Cardiovascular Diseases Prevention and Control Colchicine Therapeutic Use Major Adverse Cardiac Events Prevention and Control Colchicine Adverse Effects Study Design Recurrence Prevention and Control Dose-Response Relationship, Drug ab: This letter addresses the use of trial sequential analysis (TSA) in evaluating colchicine for secondary prevention of cardiovascular disease (CVD), responding to comments by Konipineni et al. The authors acknowledge TSA’s benefits but highlight its limitations, including sensitivity to assumptions and recommendations against its use for updated meta-analyses by the Cochrane Scientific Committee. They note that TSA results generally support colchicine’s protective effect in CVD, particularly at cumulative exposures ≥90 mg-days, and emphasize that findings from the COLCOT trial reinforce colchicine’s benefit in acute atherothrombotic CVD. The letter underscores the importance of integrating statistical methods with clinical context when interpreting evidence in cardiovascular medicine. pubtype: Academic Journal doctype: letter response Journal Article ougenre: Unknown language: English refInfo: holdings: @attributes: islocal: N |
|---|